Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of degarelix one-month depots in prostate cancer
2004-003814-40Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Nov 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Primary endpoint: Clinical safety parameters. Started Nov 2004; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-003814-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003814-40.